Peter Goldstein, Executive Director, Research and Development. Peter has 16 years of experience managing multidisciplinary scientific and technical programs. After working on anti-cancer peptides in the laboratory of Nobel Laureate Andrew Schally, he co-founded Biscayne Pharmaceuticals in 2012 (later becoming Biscayne Neurotherapeutics), where he was responsible for R&D and Clinical Operations, managing drug development programs in oncology and epilepsy in the U.S., China, and Australia. He oversaw clinical trials in epilepsy, GMP manufacturing of peptides and small molecules, pharmacokinetics & toxicology studies in multiple species, dozens of pre-clinical studies in oncology, as well as supported due diligence and intellectual property, resulting in a successful company exit. He started his career as a product manager at Ceradyne, Inc., and has consulted for pharma overseeing Phase 1-4 clinical trials. Peter holds B.S. and M.S. degrees in Materials Science and Engineering from the University of Florida.